<PAGE>

                                   FORM 10-Q


                      SECURITIES AND EXCHANGE COMMISSION

                            Washington, D.C. 20549


         [X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                        SECURITIES EXCHANGE ACT OF 1934

           For the quarterly period ended          September 30, 1999
                                          ----------------------------------


                                       OR

         [ ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                        SECURITIES EXCHANGE ACT OF 1934

            For the transition period from _____________ to _____________

                         Commission file number 1-9983

                           OEC MEDICAL SYSTEMS, INC.
                                 (Registrant)

                     Incorporated in the State of Delaware

               I.R.S. Employer Identification Number 94-2538512


            384 Wright Brothers Drive, Salt Lake City, Utah  84116
                   (Address of Principal Executive Offices)


                          Telephone:  (801) 328-9300

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such requirements
for the past 90 days.

                         Yes   X                No
                             -----                 -----
<PAGE>

As of October 29, 1999, there were 12,743,165 shares of Common Stock ($.01 par
value) outstanding.
Part I.  Financial Information
Item 1.  Financial Statements
                           OEC MEDICAL SYSTEMS, INC.
                     CONSOLIDATED STATEMENTS OF OPERATIONS
                                  (unaudited)
        FOR THE QUARTER & NINE MONTHS ENDED SEPTEMBER 30, 1999 AND 1998
                   (In thousands, except per share amounts)
<TABLE>
<CAPTION>

                                                  Quarter Ended September 30,             Nine Months Ended September 30,
                                                      1999         1998                       1999            1998
                                                     ------------------                       --------------------
<S>                                                  <C>        <C>                           <C>         <C>
Net sales
   Product                                           $32,839    $42,005                       $124,057    $117,966
   Service                                             6,199      5,875                         18,284      17,056
                                                     -------    -------                       --------    --------
      Total net sales                                 39,038     47,880                        142,341     135,022
                                                     -------    -------                       --------    --------

Cost of sales
   Product                                            19,384     23,336                         70,329      65,516
   Service                                             5,141      4,172                         14,216      12,383
                                                     -------    -------                       --------    --------
      Total cost of sales                             24,525     27,508                         84,545      77,899
                                                     -------    -------                       --------    --------
      Gross margin                                    14,513     20,372                         57,796      57,123
                                                     -------    -------                       --------    --------

Operating Expenses
  Research and development                             3,274      3,305                         10,129       9,589
  Marketing and sales                                  8,136      7,916                         25,875      23,079
  Administrative, general and other                    4,302      2,425                          9,609       7,148
                                                     -------    -------                       --------    --------
      Total operating expenses                        15,712     13,646                         45,613      39,816
                                                     -------    -------                       --------    --------

Operating income (loss)                               (1,199)     6,726                         12,183      17,307

Interest income                                          208        264                            539         754
Interest expense                                          (2)       (68)                           (16)       (213)
                                                     -------    -------                       --------    --------

Income (loss) before income taxes                       (993)     6,922                         12,706      17,848
Income tax expense (benefit)                            (347)     2,606                          4,447       6,412
                                                     -------    -------                       --------    --------
Net income (loss)                                    $  (646)   $ 4,316                       $  8,259    $ 11,436
                                                     =======    =======                       ========    ========

Net income (loss) per common share:
   Diluted                                           $ (0.05)   $  0.32                       $   0.62    $   0.85
   Basic                                               (0.05)      0.34                           0.65        0.90
Common shares:
      Diluted                                         13,470     13,354                         13,391      13,378
      Basic                                           12,702     12,709                         12,707      12,679

</TABLE>
                            (See Accompanying Notes)

                                       2
<PAGE>

                           OEC MEDICAL SYSTEMS, INC.
                          CONSOLIDATED BALANCE SHEETS
                   SEPTEMBER 30, 1999 AND DECEMBER 31, 1998
                   (In thousands, except per share amounts)

                                     ASSETS
<TABLE>
<CAPTION>
                                                                  September 30, 1999   December 31, 1998
                                                                  -------------------  -----------------
                                                                      (unaudited)
<S>                                                                  <C>                  <C>
Current Assets:
 Cash and cash equivalents                                             $  7,684            $  4,438
 Securities available for sale                                           11,618              15,222
 Accounts receivable, net of allowances of $1,288                        40,299              44,365
 Inventories, net                                                        53,243              42,579
 Prepaid expenses and other current assets                                1,754               1,079
 Income taxes receivable                                                    295                 629
 Deferred income taxes                                                    5,872               6,698
                                                                       --------            --------
    Total current assets                                                120,765             115,010

Long-term receivables                                                       700               1,520
Property and equipment, net                                              17,316              17,242
Cost in excess of net assets acquired, net of
 accumulated amortization of $10,854 and $10,126, respectively            9,194               9,922
Deferred income taxes                                                       755                 256
Investment in unconsolidated affiliate                                    2,381               1,421
Other assets                                                              1,136                 876
                                                                       --------            --------
    Total                                                              $152,247            $146,247
                                                                       ========            ========


                      LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:
 Accounts payable                                                      $ 11,982            $ 12,101
 Accrued salaries and benefits                                            6,903               6,485
 Accrued warranty and installation costs                                  2,677               2,702
 Deferred income and customer deposits                                    4,933               4,647
 Accrued distributor commissions                                          2,836               3,795
 Other accrued liabilities                                                5,106               4,548
                                                                       --------            --------
    Total current liabilities                                            34,437              34,278
                                                                       --------            --------


Stockholders' Equity:
 Preferred stock, $.01 par value
    Authorized--2,000 shares, none outstanding                               --                  --
 Common stock, $.01 par value
    Authorized--30,000 shares
    Issued--14,170 and 13,976 shares, respectively                          142                 140
 Capital in excess of par value                                          92,463              88,990
 Retained earnings                                                       46,325              38,066
 Treasury stock, 1,445 and 1,200 shares at cost, respectively           (20,741)            (15,036)
 Accumulated other comprehensive income                                    (379)               (191)
                                                                       --------            --------
    Total stockholders' equity                                          117,810             111,969
                                                                       --------            --------
      Total                                                            $152,247            $146,247
                                                                       ========            ========
</TABLE>
                            (See Accompanying Notes)


                                       3
<PAGE>

                           OEC MEDICAL SYSTEMS, INC.
                     CONSOLIDATED STATEMENTS OF CASH FLOWS
             FOR THE NINE MONTHS ENDED SEPTEMBER 30, 1999 AND 1998
                                (In thousands)
                                  (unaudited)

<TABLE>
<CAPTION>
                                                                        1999       1998
                                                                      --------   --------
<S>                                                                   <C>        <C>
OPERATING ACTIVITIES:
   Net income                                                         $  8,259   $ 11,436
   Adjustments to reconcile net income
       to net cash provided by operating activities:
       Depreciation and amortization expense                             4,057      3,600
       Deferred income tax expense                                         327        433
       Current tax benefit attributable to stock options exercised         716      2,281
       Non-employee stock option expense                                   147         --
       Changes in current assets and liabilities:
            Accounts receivable, net                                     4,066        390
            Inventories, net                                           (10,664)   (12,916)
            Prepaid expenses and other current assets                     (675)     2,139
            Income taxes                                                   334       (368)
             Other assets                                                 (260)       955
             Accounts payable                                             (119)      (126)
             Accrued salaries and benefits                                 418      1,993
             Accrued warranty and installation costs                       (25)       765
             Deferred income and customer deposits                         286        386
             Accrued legal fees and litigation settlements                  --        380
             Accrued distributor commissions                              (959)      (837)
             Other accrued liabilities                                     558       (417)
                                                                      --------   --------
       Net cash provided by operating activities                         6,466     10,094
                                                                      --------   --------

INVESTING ACTIVITIES:
   Reduction (increase) in long-term receivables                           820       (121)
   Additions to property and equipment                                  (3,217)    (4,641)
   Sale (purchase) of securities available for sale                      3,604     (3,883)
   Payment for the purchase of unconsolidated affiliate                 (1,140)    (1,575)
   Other                                                                  (188)       (39)
                                                                      --------   --------
       Net cash used by investing activities                              (121)   (10,259)
                                                                      --------   --------

FINANCING ACTIVITIES:
   Common stock issued under benefit plans                               2,612      3,457
   Purchases of treasury stock                                          (5,705)    (4,580)
                                                                      --------   --------
       Net cash used by financing activities                            (3,093)    (1,123)
                                                                      --------   --------

   Net increase (decrease) in cash and cash equivalents                  3,246     (1,288)
   Cash and cash equivalents at beginning of period                      4,438     17,502
                                                                      --------   --------
   Cash and cash equivalents at end of period                         $  7,684   $ 16,214
                                                                      ========   ========

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
   Cash paid during the period for interest                           $     16   $     25
</TABLE>

                                       4
<PAGE>

<TABLE>
   <S>                                                                <C>        <C>
   Cash paid during the period for income taxes                       $  3,154   $  2,741
</TABLE>

                           (See Accompanying Notes)

                                       5
<PAGE>

                           OEC MEDICAL SYSTEMS, INC.
                  NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                  (UNAUDITED)
                          SEPTEMBER 30, 1999 AND 1998


1.   Interim information is unaudited but, in the opinion of Company management,
     all adjustments necessary for a fair presentation of interim results have
     been included. The results for the three and nine months ended September
     30, 1999 and 1998, are not necessarily indicative of the results to be
     expected for the entire year. These consolidated financial statements and
     notes should be read in conjunction with the Company's consolidated
     financial statements for the year ended December 31, 1998, filed on Form
     10-K on March 25, 1999.

2.   Inventories are stated at the lower of cost, utilizing the first-in/first-
     out method, or market. Inventories consist of the following:

<TABLE>
<CAPTION>
                                                               September 30,   December 31,
                                                                    1999           1998
                                                                    ----           ----
                                                                      (In thousands)
          <S>                                                  <C>             <C>
          Purchased parts and completed subassemblies            $25,879         $21,893
          Work-in-process                                          7,869           5,816
          Finished goods                                           1,608           2,268
          Demonstration equipment                                 14,996          11,476
          Service and repair parts                                 8,165           5,870
                                                                 -------         -------
          Total                                                   58,517          47,323
          Less: reserves for excess and obsolete inventory        (5,274)         (4,744)
                                                                 -------         -------
          Net                                                    $53,243         $42,579
                                                                 =======         =======
</TABLE>

3.   The Company has adopted Statement of Financial Accounting Standards
     ("SFAS") No. 130, "Reporting Comprehensive Income." SFAS No. 130
     establishes new rules for the reporting and display of comprehensive income
     and its components, however, it has no impact on the Company's net income.

     The components of comprehensive income are as follows:

<TABLE>
<CAPTION>
                                                      Nine Months Ended September 30,   Nine Months Ended September 30,
                                                                    1999                              1998
                                                                    -----                             ----
                                                                                 (In thousands)
          <S>                                         <C>                               <C>
          Net income                                              $8,259                            $11,436
          Foreign currency translation adjustments                  (188)                               (39)
                                                                  ------                            -------
          Total comprehensive income                              $8,071                            $11,397
                                                                  ======                            =======
</TABLE>

     In June 1999, the Financial Accounting Standards Board (FASB) issued
     Statement of Financial Accounting Standards (SFAS) No. 137 "Accounting for
     Derivative Instruments and Hedging Activities - Deferral of the Effective
     Date of FASB Statement No. 133." SFAS No. 137 delays the effective date of
     SFAS No. 133 to fiscal years beginning after June 15, 2000. The Company
     will adopt the new statement beginning on January 1, 2001. The Company does
     not believe that SFAS 133, as amended by SFAS 137, will have a significant
     effect on the earnings and financial position of the Company.

4.   On July 7, 1999 the Company agreed to increase its minority equity interest
     in Heartlab, Inc., a medical imaging software development company, by
     investing an additional $1.1 million. The Company agreed to increase the

                                       6
<PAGE>

     investment by up to an additional $0.8 million if Heartlab, Inc. met
     certain profitability criteria over the next year. The Company will
     continue to account for this investment using the equity method of
     accounting.

5.   On August 9, 1999, the Company announced that it had signed a definitive
     agreement to merge its operations with the GE Medical Systems business of
     General Electric Company (NYSE: GE). In this transaction, Company
     shareholders will receive approximately $36 per share payable in GE stock.
     The actual number of shares of GE stock that each Company shareholder will
     receive will be based on the trading prices of GE stock for a period of
     time prior to the closing of the transaction. OEC Shareholders plan to vote
     on the proposed merger at a Special Meeting scheduled for November 29, 1999
     and the transaction is expected to close immediately thereafter. The boards
     of directors of both GE and the Company have approved the merger. In
     connection with the merger agreement, the Company granted GE an option to
     acquire newly issued shares of the Company common stock, representing 15%
     of its total shares outstanding, at the $36 per share transaction price.

                                       7
<PAGE>

                           OEC MEDICAL SYSTEMS, INC.
                ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                 FINANCIAL CONDITION AND RESULTS OF OPERATIONS


Except for historical information, this discussion contains forward-looking
statements that involve risks and uncertainties that could cause actual results
to differ materially from those projected. Such risk and uncertainties include
those described in the "Factors That May Affect Future Operations" section on
page 8 of this Form 10-Q.

Results of Operations
---------------------

For the third quarter ended September 30, 1999, OEC Medical Systems, Inc. had a
net loss of $0.6 million and for the nine months ended September 30, 1999, the
Company had net income of $8.3 million, compared with net income of $4.3 million
and $11.4 million, respectively, for the same periods in 1998.

During the third quarter, the Company encountered transition issues with the
introduction of the Series 9800 Mobile C-arm, which delayed production at the
beginning of the quarter. Although these issues were resolved by mid-August, the
reduced shipments adversely affected revenue and income.

On August 9, 1999, the Company announced that it had signed a definitive
agreement to merge with the GE Medical Systems business of General Electric
Company, subject to shareholder approval. During the third quarter, the Company
had $1.5 million of merger related costs. Excluding merger expenses, the Company
would have earned $0.02 per share for the quarter.

The following table sets forth OEC's operating results as a percentage of net
sales:

<TABLE>
<CAPTION>
                                                   Quarter Ended September 30,     Nine Months Ended September 30,
                                                       1999           1998                1999           1998
                                                       -------------------                -------------------
          <S>                                      <C>               <C>           <C>                  <C>
          Net sales:
           Product                                      84.1          87.7                 87.2          87.4
           Service                                      15.9          12.3                 12.8          12.6
                                                       -----         -----                -----         -----
              Total net sales                          100.0         100.0                100.0         100.0
                                                       -----         -----                -----         -----

          Cost of sales:
           Product                                      49.7          48.8                 49.4          48.5
           Service                                      13.1           8.7                 10.0           9.2
                                                        ----         -----                -----         -----
            Total cost of sales                         62.8          57.5                 59.4          57.7
                                                       -----         -----                -----         -----
           Gross margin                                 37.2          42.5                 40.6          42.3
                                                       -----         -----                -----         -----

          Operating expenses:
           Research and development                      8.4           6.9                  7.1           7.1
           Marketing and sales                          20.8          16.5                 18.2          17.1
           Administrative, general and other            11.1           5.1                  6.7           5.3
                                                       -----         -----                -----         -----
            Total operating expenses                    40.3          28.5                 32.0          29.5
                                                       -----         -----                -----         -----

          Operating income (loss)                       (3.1)         14.0                  8.6          12.8
                                                       -----         -----                -----         -----

          Net income (loss)                             (1.7)          9.0                  5.8           8.5
                                                       =====         =====                =====         =====
</TABLE>

Sales and Markets
-----------------

Net sales for the quarter and nine months ended September 30, 1999, were $39.0
million and $142.3 million, respectively, compared with net sales of $47.9
million and $135.0 million for the comparable periods of 1998.  This reflects an
18% decrease and 5% increase, respectively, and is a direct result of transition
issues with the introduction of the Series 9800.  Product sales for the quarter
and nine months ended September 30, 1999 were

                                       8
<PAGE>

$32.8 million and $124.1 million, respectively, compared with product sales of
$42.0 million and $118.0 million, respectively, for the same periods last year.

The order rate in the third quarter was down 12% over last year, and for the
nine months was up 4%, with strong international bookings partially offsetting
the slowdown of domestic orders associated with the introduction of the Series
9800.

Service revenue for the quarter and nine months ended September 30, 1999 was
$6.2 million and $18.3 million, respectively, compared with service revenue of
$5.9 million for the same quarter last year and $17.1 million for the nine month
period in 1998.

International revenue was up 35% for the nine-month period, compared to the
prior year. The significant increases are partially due to strong growth in
Europe as well as improvements in the economic conditions in Asia.

Margin Analysis
---------------

OEC's gross margin was 37.2% of net sales for the third quarter and 40.6% for
the nine months of 1999, compared to 42.5% and 42.3%, respectively, for the same
periods in 1998.  The decline in margin was due to production start-up costs
with the introduction of the Series 9800, the increased international sales that
typically have a lower selling price and additional discounting of the Series
9600 as that product nears the end of its product life cycle.

Service expenses increased by $1.0 million in the third quarter and $1.8 million
for the nine months, compared to the same periods in 1998.  The increases are
due to additional personnel and the start-up costs associated with restructuring
the Company's service support in Texas, Iowa and Nebraska.

Operating Expenses
------------------

Research and development costs were flat for the three-month period and up $0.5
million for the nine months compared to the prior year.

Marketing and sales expenses were flat for the quarter and increased $2.8
million or 12% for the nine months compared to the prior year, primarily due to
additional commission expense associated with the increased revenue and the
start-up costs required for restructuring the Company's product distribution
channel in Texas.

Administrative expenses included $1.5 million of merger related costs.
Excluding the merger costs, administrative expenses increased 14% for the nine
months ended September 30, 1999 compared to the prior year.

Income Taxes
------------

For the first nine months of 1999 and 1998, the Company recorded $4.4 million
and $6.4 million of tax expense, respectively.  The effective tax rate remains
at 35% and it is expected to remain around that level throughout 1999.

Liquidity and Capital Resources
-------------------------------

Cash provided by operations for the nine months ended September 30,1999 and 1998
was $6.4 million and $10.1 million, respectively.  During 1999, cash generated
from net income was partially offset by inventory increases associated with the
production delays of the Series 9800.

At the beginning of the third quarter, the Company increased its minority
interest investment in Heartlab, Inc. by an additional $1.1 million.

Factors That May Affect Future Results
--------------------------------------

Certain statements contained in this document and other written and oral
statements made from time to time by the Company do not relate strictly to
historical or current facts.  As such, they are considered "forward-looking
statements" which provide current expectations or forecasts of future events.
Such statements can be identified by

                                       9
<PAGE>

the use of terminology such as "anticipate," "believe," "estimate," "expect,"
"intend," "may," and similar words or expressions. The Company's forward-looking
statements generally relate to its growth strategies, financial results, product
development and regulatory approval programs, and sales efforts. One must
carefully consider forward-looking statements and understand that such
statements involve a variety of risks and uncertainties, known and unknown, and
actual results may vary materially.

OEC's future operating results are dependent on its ability to develop,
manufacture and market innovative products that meet customers' needs.  The
process of developing new high technology medical products is complex and
uncertain and requires innovative designs that anticipate customer needs,
technological trends and healthcare shifts. There can be no assurance that the
Company will be able to develop and market new products on a cost-effective and
timely basis, that such products will compete favorably with products developed
by others or that existing technology will not be superceded by new discoveries
or breakthroughs.

In May 1999, the Company introduced its new Series 9800 1k x 1k product
platform, which is the next generation successor to the Company's Series 9600
platform.  As previously reported, the Company has encountered transition issues
often associated with new product introductions and the Company experienced a
related shortfall in revenue and profits for the third quarter of 1999. Although
the Company believes that the significant issues have been resolved, there may
be additional issues related with the new product's introduction.

Because of the substantial length of time and expense associated with bringing
new products through development and regulatory approval to the marketplace, the
medical device industry places considerable importance on obtaining patent,
trademark, copyright and trade secret protection for new technologies, products
and processes.  The loss of such protection could have a material adverse effect
on the Company's business.

OEC depends on some significant vendors for certain important component parts
for certain products.  While the Company believes any of these single-source
items could be replaced over time, abrupt disruption in the supply of a part for
a product could have an adverse effect on the Company's production and on its
financial condition and results of operations in cases where the existing
inventory of the components is not adequate to meet the Company's demand for the
component during such disruption.

The testing, marketing and sale of human healthcare products entails an inherent
risk of product liability.  There can be no assurance that product liability
claims will not be asserted against OEC.  Although OEC has product liability
insurance coverage, there can be no assurance that such coverage will provide
adequate coverage against all potential claims.

As a manufacturer of medical devices, OEC is subject to extensive and rigorous
governmental regulation, principally by the FDA and corresponding state and
foreign agencies.  Failure to comply with FDA and other regulations could result
in sanctions being imposed, including restrictions on the marketing of or recall
of the affected products.  OEC's facilities and manufacturing processes have
been periodically inspected by the FDA and other agencies, but remain subject to
further inspections from time to time.  OEC continues to devote substantial
human and financial resources to regulatory compliance and believes that it
remains in substantial compliance with all applicable federal and state
regulations.  Nevertheless, there can be no assurance that the FDA or a state or
foreign agency will agree with OEC's positions, or that its GMP or ISO
compliance will not be challenged at some subsequent point in time.

A portion of the Company's research and development activities, some of its
single-source vendors, its corporate headquarters and other critical business
operations are located near a major earthquake fault.  The ultimate impact on
the Company, significant suppliers and the general infrastructure is unknown,
but operating results could be materially affected in the event of a major
earthquake.

Although OEC believes that it has the product offerings and resources needed for
continuing success, future revenue and margin trends cannot be reliably
predicted and may cause the Company to adjust its operations.  Factors external
to the Company can result in volatility of the Company's common stock price.

                                       10
<PAGE>

Foreign Currency Rate Exposure

The Company has operating subsidiaries located in Europe and utilizes forward
exchange contracts with durations generally less than six months to hedge
against the effect of exchange rate fluctuations of European income.   The
Company's forward exchange contracts are not material.  The Company also has
other customers located throughout the world; however, these customers' invoices
are denominated in U.S. dollars.  As a result, the Company has not incurred
material gains or losses resulting from foreign currency fluctuations.  However,
adverse fluctuations of exchange rates can affect the purchasing power of
international customers that can result in volatility of international demand.

Interest Rate Risk Exposure

The Company has purchased certain debt obligations of the U.S. government and
various corporations with original maturities of less than one year.  As of
September 30, 1999, such investments totaled approximately $11.6 million and the
difference between fair market value and amortized cost is immaterial.  Interest
rate risk and default risk underlying these securities is not considered to be
significant.

Other Exposures

The Company has not entered into any speculative derivatives and does not
foresee utilizing such instruments in the future.  The Company does not utilize
commodities in the normal course of its manufacturing process.  Accordingly, the
Company does not believe it has any significant commodity risks or exposures.

Year 2000 Readiness Disclosure

The Company has completed a review of its business information systems with
respect to Year 2000 compliance and will either replace or correct those
computer systems that have been found to have date-related deficiencies.  New
integrated business information systems for the order administration, financial
and manufacturing processes were put in place in 1997.  A few minor corrective
actions are required to make these systems Year 2000 compliant and these
corrections had been completed by the end of the third quarter 1999.  The
business information system for the service operations is being replaced with a
planned completion date of November 1999.

The Company's products being shipped today have been assessed and found to be
Year 2000 compliant provided that the user perform a reset of the date upon
first use in the Year 2000.  The Company believes that products previously
shipped are either Year 2000 compliant or can be made Year 2000 compliant with
the purchase of an upgrade or a date reset performed upon first use in the Year
2000.

The Company is also assessing facility and telecommunications systems and
systems used to support the product design and manufacturing processes to ensure
that these will be Year 2000 ready.  It is anticipated that any required
corrective actions will be complete by mid fourth quarter 1999.

The Company relies on third party providers for materials and services such as
telecommunications, utilities, financial services and other key services.
Interruption of those materials or services due to Year 2000 issues could affect
the Company's operations.  The Company has completed the process of contacting
its major suppliers and has determined that all major suppliers are in the
process of ensuring Year 2000 compliance.  However, since the Company is
dependent on key third parties, there can be no guarantee that the Company's
efforts will prevent a material adverse impact on its financial position,
results of operations or liquidity in future periods in the event that a
significant number of suppliers and/or customers experience business disruptions
as a result of their lack of Year 2000 readiness.

The Company estimates that it has incurred costs of approximately $4 million, to
date, in external and internal costs to address its Year 2000 readiness issues,
the majority of which are the new business information systems installed in
1997.  The Company currently estimates that it will incur additional costs of
approximately less than $1 million to complete its Year 2000 readiness projects.

                                       11
<PAGE>

Both the Company's cost estimates and completion time frames could be influenced
by its ability to successfully identify all Year 2000 issues, the nature and
amount of corrective action required, the availability and cost of trained
personnel in this area and the Year 2000 success that key third parties and
customers attain.  While these and other unforeseen factors could have a
material adverse impact on the Company's financial position, results of
operations or liquidity in future periods, management believes that it has
implemented an effective Year 2000 compliance program that will minimize the
possible negative consequences to the Company.

Throughout 1999, the Company has determined areas where contingency planning is
needed.  The planning efforts have included, but are not limited to,
identification and mitigation of potential serious business interruptions,
adjustments of inventory levels to meet customer needs, and establishing crisis
response processes to address unexpected problems.  Due to the November 1999
completion date for the replacement of the business information system for
service operations, the Company has developed contingency plans for the
potential business interruptions if this system fails.  The contingency plan
includes utilizing current existing systems, instituting manual processes and
utilizing increased inventory levels.  In addition, the Company has increased
inventory levels to mitigate the risk of an interruption in the delivery of
materials by its suppliers for current production as well as service support.

Part II.  Other information

Item 1.   Legal proceedings

There are no significant changes in legal proceedings from the previous stated
position in the Company's Annual Report for 1998 or Form 10K filed with the
Securities & Exchange Commission on March 25, 1999.

Item 5.   Other Information

On August 9, 1999, the Company announced that it had signed a definitive
agreement to merge its operations with the GE Medical Systems business of
General Electric Company (NYSE: GE).  In this transaction, Company shareholders
will receive approximately $36 per share payable in GE stock.  The actual number
of shares of GE stock that each Company shareholder will receive will be based
on the trading prices of GE stock for a period of time prior to the closing of
the transaction.  OEC Shareholders plan to vote on the proposed merger at a
Special Meeting scheduled for November 29, 1999 and the transaction is expected
to close immediately thereafter.  The boards of directors of both GE and the
Company have approved the merger.  In connection with the merger agreement, the
Company granted GE an option to acquire newly issued shares of the Company
common stock, representing 15% of its total shares outstanding, at the $36 per
share transaction price.

                                       12
<PAGE>

Item 6.  Exhibits

(a)    The following exhibit (numbered in accordance with Item 601 of SEC
Regulations S-K) is filed as part of this report:

       Exhibit
       Number       Description
       --------

        3.1      Certificate of Incorporation, as amended. Incorporated by
                 reference to the OEC MedicalSystems, Inc. Form 10-K, filed
                 March 30, 1994.

        3.2      By-Laws, as amended May 15, 1997. Incorporated by reference to
                 the OEC Medical Systems, Inc. Form 10-Q, filed August 8, 1997.

        10.4     Diasonics, Inc. 1990 Stock Option/Stock Purchase Plan.
                 Incorporated by reference to Exhibit 10.79 of the Diasonics,
                 Inc. Form S-8, filed on May 1, 1991.

        10.14    Form of Option Agreement used in connection with options having
                 service-vesting provisions. Incorporated by reference to the
                 OEC Medical Systems, Inc. Form S-8, filed June 12, 1998.

        10.15    Form of Option Agreement used in connection with options having
                 milestone provisions.Incorporated by reference to the OEC
                 Medical Systems, Inc. Form S-8, filed June 12, 1998.

        10.16    Form of Option Agreement used in connection with automatic
                 option grant program for non-employee directors. Incorporated
                 by reference to the OEC Medical Systems, Inc. Form S-8, filed
                 June 12, 1998.

        10.20    Form of Warrant Agreement used in connection with grant to
                 independent contractors for the purchase of common shares.
                 Incorporated by reference to the OEC Medical Systems, Inc. Form
                 10-K, filed March 27, 1997.

        10.24    OEC Medical Systems, Inc. 1993 Employee Incentive Stock
                 Acquisition Plan, as amended and re-stated March 31, 1998.
                 Incorporated by reference to the OEC Medical Systems, Inc. Form
                 S-8, filed June 12, 1998.

        10.25    OEC Medical Systems, Inc. 1998 Stock Option Plan. Incorporated
                 by reference to the OEC Medical Systems, Inc. Form S-8, filed
                 June 12, 1998.

        10.26    Form of Option Agreement used in connection with the granting
                 of incentive stock options. Incorporated by reference to the
                 OEC Medical Systems, Inc. Form S-8, filed June 12, 1998.

        10.27    Agreement and Plan of Merger among General Electric Company,
                 Ruby Merger Corp. and OEC Medical Systems, Inc. dated August 7,
                 1999. Incorporated by reference to the OEC Medical Systems,
                 Inc. Form 10-Q filed August 13, 1999 .

        10.28    Stock Option Agreement between General Electric Company and OEC
                 Medical Systems, Inc. dated August 7, 1999. Incorporated by
                 reference to the OEC Medical Systems, Inc. Form 10-Q filed
                 August 13, 1999.

        10.29    Proxy Statement dated October 1, 1999. Incorporated by
                 reference to the OEC Medical Systems, Inc. Form DEF M14A filed
                 October 1, 1999.

        10.30    Form of Warrant Purchase Agreement used in connection with the
                 purchase of warrants previously granted to independent
                 contractors.

           11    Statement of Computation of Per Share Earnings.

                                       13
<PAGE>

           21    List of Subsidiaries. Incorporated by reference to the OEC
                 Medical Systems, Inc. Form 10-Q, filed May 13, 1997.

           27    Financial Data Schedule (FDS) for Edgar Filing.

            (b)  Reports on Form 8-K:
                 Not Applicable

                                       14
<PAGE>

                                  SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


OEC MEDICAL SYSTEMS, INC.
(Registrant)



By: /s/ Randy W. Zundel
    ------------------------------
    Randy W. Zundel
    Chief Financial Officer
    (Principal Accounting Officer)


Date:  November 5, 1999

                                       15